Exploring nonviral reprogramming for diabetes treatment using extracellular vesicles

Introduction to Diabetes and β Cell Replacement Therapy

Diabetes is a chronic condition that affects millions of people worldwide. It is characterized by the body’s inability to produce or properly use insulin, a hormone crucial for regulating blood sugar levels. For individuals with insulin-dependent diabetes, replacing lost or dysfunctional insulin-producing β cells in the pancreas is a promising treatment approach. Traditional methods for β cell replacement often rely on progenitor or stem cells, which can be complex and challenging to manage.

The Potential of Direct Nuclear Reprogramming

Direct nuclear reprogramming offers an exciting alternative for developing β cell replacement therapies. This approach involves directly converting one type of mature cell into another, bypassing the need for intermediate stem cell stages. Despite its promise, current methods for β cell reprogramming often depend on viral vectors to deliver the necessary genetic instructions, which can pose safety and efficiency concerns.

A Novel Approach: Using Extracellular Vesicles (EVs)

Researchers at the Ohio State University are now exploring the use of extracellular vesicles (EVs) as nonviral carriers for reprogramming factors. EVs are tiny particles released by cells that can carry proteins, RNA, and other molecules between cells. This study focuses on using EVs derived from human dermal fibroblasts (HDFs) to deliver specific transcription factors to pancreatic ductal epithelial cells (PDCs) to induce their transformation into insulin-producing cells.

The Process of Using EVs for Cell Reprogramming

  1. Electrotransfection of HDFs: The researchers started by using a technique called electrotransfection to introduce expression plasmids for three crucial transcription factors—Pdx1, Ngn3, and MafA (collectively known as PNM)—into HDFs. These factors are key in guiding cells to develop into β cells.
  2. Loading EVs with PNM: Once transfected, the HDFs released EVs loaded with PNM at the gene, mRNA, and protein levels.
  3. Transfecting PDCs with EVs: The PNM-loaded EVs were then used to treat cultures of PDCs. The EVs successfully delivered the PNM transcription factors into the PDCs, increasing their expression of these crucial proteins.
  4. Inducing Endocrine Conversion: The presence of PNM in PDCs led to their transformation into cells that express insulin/c-peptide, glucagon, and glucose transporter 2 (Glut2), indicating successful reprogramming into endocrine cells.

In Vivo Validation

To confirm their findings, the researchers tested the approach in a mouse model. They injected PNM-loaded EVs directly into the pancreatic ducts of mice. The results showed successful reprogramming of pancreatic cells into hormone-expressing cells, further supporting the potential of this technique.

Implications for Diabetes Treatment

These findings suggest that EVs derived from dermal fibroblasts can serve as a powerful platform for nonviral reprogramming-based therapies. This method could offer a safer and potentially more efficient way to develop β cell replacement therapies for treating insulin-dependent diabetes. By avoiding viral vectors, this approach reduces the risks associated with genetic modifications and opens new avenues for cell therapy development.


The use of extracellular vesicles (EVs) for direct nuclear reprogramming represents a significant advancement in the field of diabetes treatment. This innovative approach has the potential to revolutionize β cell replacement therapies, offering a nonviral, efficient, and safer method for transforming cells to produce insulin. As research progresses, this technology could pave the way for new, effective treatments for individuals with insulin-dependent diabetes, improving their quality of life and health outcomes.

Ortega-Pineda L, Guilfoyle E, Rincon-Benavides MA, Anaparthi AL, Lemmerman LR, Cuellar-Gaviria TZ, Lawrence W, Buss JL, Deng B, Blackstone BN, Salazar-Puerta A, McComb DW, Powell H, Gallego-Perez D, Higuita-Castro N. (2024) Engineered extracellular vesicles from human skin cells induce pro-β-cell conversions in pancreatic ductal cells. Adv Nanobiomed Res 3(10):2200173. [article].

Leave a Reply

Your email address will not be published. Required fields are marked *